drugset / Trial / NCT05964790
Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10380 relative to placebo for the treatment of participants with schizophrenia.
Timeline
- Start
- 2023-07-30
- Primary completion
- 2024-06-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10380 | Unknown | 1.5 mg | Oral |